
Douglas County faces lawsuit over tax-forfeited properties
Mar. 25—DOUGLAS COUNTY — Douglas County is among many Wisconsin governmental entities being sued over property taken for unpaid taxes.
Every Wisconsin county, the state and the city of Milwaukee have been named as defendants in a lawsuit filed Feb. 17 in Waukesha County Circuit Court on behalf of residents who had their property taken for unpaid taxes but were denied proceeds of the sale that exceeded the taxes they owed between Jan. 1, 1989, and April 2, 2022.
"We were just following the law," said Mark Liebaert, Douglas County Board chairman.
"The Wisconsin state legislature implemented a statutory scheme to cause its political subdivisions, namely, the county defendants, to systematically and repeatedly take property unconstitutionally without just compensation," the lawsuit claims. "The Wisconsin judiciary approved of, and gave color of law to, the state of Wisconsin's unconstitutional scheme."
Prior to April 2, 2022, the law generally authorized the county to retain the net proceeds from the sale of tax-delinquent property unless the property was used by the former owner as a homestead at any time in the preceding five years, according to a Wisconsin Legislative Council memo about 2021 Wisconsin Act 216, which changed the law.
If the property had recently been used as a homestead, the county was required to notify the former owner that they may be entitled to a share of the proceeds. Unless the former owner requested payment within 60 days of receiving the notice, the former owner forfeited all claims to the proceeds.
Act 216 entitled former owners of tax-delinquent properties, regardless of use, to receive the proceeds of the sale minus the taxes owed and the cost of satisfying liens against the property at the time of the sale. The act required the county to pay the liens.
"Recognizing the illegality of these unconstitutional takings, in 2022, Wisconsin amended its statutes to acknowledge the rights of tax-foreclosed property owners to recover the surplus generated by tax foreclosure sales," the complaint states. "However, that legislative change was only made on a forward-looking basis."
Since the change in the law, Douglas County has kept a detailed log of all tax-foreclosed properties sold. But prior to 2022, the county didn't keep records of those, said County Clerk Kaci Lundgren.
In each of the eight cases cited — none of them naming Douglas County directly — the plaintiffs' properties were taken for unpaid taxes and were subsequently sold by the county where the property was located for more than the taxes owed. Once taxes were satisfied, the counties accused directly in the lawsuit pocketed between $20,000 and $417,000 from the sale of those properties, according to the complaint.
Attorneys from Zimmer & Rens LLC of Brookfield, Wisconsin, and Milberg Coleman Bryson Phillips and Grossman PLLC, a class action specialist with offices throughout the United States, are representing the plaintiffs named in the suit and all similarly situated individuals. They cite violations of the excessive fines and takings clauses of the Wisconsin and U.S. constitutions.
Liebaert worries the lawsuit could cost Douglas County millions unless the state steps up.
The state of Minnesota settled similar lawsuits last year for $109 million
after the U.S. Supreme Court ruled
in 2023 in the case of Geraldine Tyler, 94, of Minneapolis.
Tyler sued Hennepin County after the county sold her tax-forfeited condominium for $40,000 and kept the money. At the time, Tyler owed about $15,000 in unpaid property taxes, interest and fees.
The justices were unanimous in ruling that Hennepin County's retention of the excess value of Tyler's home above the taxes owed violated the takings clause of the Fifth Amendment of the U.S. Constitution. The court did not rule on Tyler's allegation that the county had also violated the excessive fines clause under the Eighth Amendment; however, Justices Neil Gorsuch and Ketanji Brown Jackson addressed the matter in a separate opinion.
"Economic penalties imposed to deter willful noncompliance with the law are fines by any other name," Gorsuch and Jackson wrote. "And the Constitution has something to say about them: They cannot be excessive."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
07-05-2025
- Yahoo
Zimmer Biomet expects $60M to $80M tariff impact this year
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. By the numbers Q1 revenue: $1.91 billion 1.1% increase year over year Net income: $182.6 million 5.6% increase year over year Zimmer Biomet expects a $60 million to $80 million impact to its operating profit from tariffs this year, CFO Suketu Upadhyay told investors Monday. That estimate accounts for 'current administration proposals,' Upadhyay said, including announced European reciprocal tariffs going into effect after a 90-day stay. Most of the impact is expected in the second half of the year. Zimmer's stock fell by more than 11% on Monday, as analysts called out uncertainty about tariffs and lost market share in the company's knees segment. J.P. Morgan analyst Robbie Marcus wrote in a research note that the tariff impact looks 'manageable at face value, but we have more questions than answers on the size of the full-year impact in 2026.' BTIG analyst Ryan Zimmerman added that the 2026 impact remains an 'open-ended question,' and the orthopedics company's inventory levels suggest that tariffs will show up more meaningfully next year. Zimmer lowered its adjusted earnings per share forecast by 25 cents to a range of $7.90 to $8.10 for 2025. The forecast factors in the tariffs and the $1.1 billion purchase of Paragon 28, a company specializing in foot and ankle implants, which closed in April. At the same time, the company raised its revenue growth forecast for the year to a range of 5.7% to 8.2%, accounting for foreign currency rates and the Paragon acquisition. Zimmer forecast a smaller hit from tariffs than other medtech peers, which have set out estimates in the hundreds of millions of dollars. For example, competitor Stryker called out a $200 million impact from tariffs, and lowered its earning per share forecast. When asked about this, Upadhyay said the majority of Zimmer's devices are produced in the U.S. Still, the company is taking some early steps to mitigate the impact, including optimizing country of origin, using dual sourcing or redundant sourcing when possible, and spending less in areas that don't affect the company's long-term growth, the CFO added. Lost share in knees Zimmer reported $792.9 million in sales from its knees business in the first quarter, a 0.6% increase year over year. Meanwhile, competitor Stryker, which reported sales of $639 million in knees, grew at a faster rate of 8.7%.
Yahoo
06-05-2025
- Yahoo
Zimmer Biomet flags $60m-$80m tariff impact on 2025 profits
Zimmer Biomet has adjusted its 2025 earnings forecast to $7.90-$8.10 per share, down from previous estimates falling between $8.15-$8.35, due to the Trump administration's tariffs. The orthopaedic giant's stock fell by almost 12% after revealing on 5 May that tariffs would contribute to a $60m-$80m drag on its operating profit in 2025. Zimmer elaborated on the revised projections in its Q1 2025 earnings call. During the quarter, the company achieved around $1.9bn in net sales, indicative of a 1.1% increase on a constant currency basis. Zimmer's chief financial officer and finance, operations and supply chain EVP Suketu Upadhyay noted that while the tariff situation 'remains fluid', the company anticipates an impact of a '$60m to $80m' headwind to operating profit in 2025, with the 'majority' of the impact falling in the second half of the year. Upadhyay said: 'This estimate contemplates our latest view of mitigation efforts currently underway and that the announced European reciprocal tariffs will go into effect after the 90-day stay period.' Along with Zimmer's recent $1.2bn acquisition of Paragon 28 earlier this year, due to tariffs, the company anticipates its full-year operating margins to be down by 100 to 150 basis points versus 2024. Upadhyay added: 'I will note that our 2025 impact should not be used as a run rate for 2026 due to a variety of factors, and that our estimate around the impact of tariffs in 2025 could change as the macro environment continues to unfold.' While noting that the majority of its manufacturing is undertaken within the US, Zimmer also has manufacturing sites in the Chinese cities of Jintan and Zhejiang. Trump's tariffs have heavily targeted China, with levies rising since the nation imposed 34% tariffs in response to those Trump announced would come into force on Chinese imports on 9 April. While the president has since stated that levies for goods imported from the country will 'come down substantially' yet 'won't be zero', they remain at 145% for now. To mitigate some of the tariff impact, Upadhyay also shared that Zimmer is optimising 'in our view of country of origin', potentially alluding to a diminishment in its China-based manufacturing activities. Other players in the medtech space are attempting to factor in the impact the Trump administration's current tariff measures may have on their bottom line in 2025. Anticipating that its 2025 revenues may take a hit of around $500m, imaging giant GE HealthCare has downshifted its earnings per share profit to fall within the $3.90-$4.10 per share range, down from previous guidance between $4.61 and $4.75 per share.
Yahoo
05-05-2025
- Yahoo
Zimmer Biomet lowers 2025 profit forecast on acquisition costs, tariff uncertainty
(Reuters) -Zimmer Biomet Holdings on Monday lowered its full-year adjusted profit forecast, as the medical device maker anticipates a hit from its recent acquisition of Paragon 28, currency volatility, and proposed tariffs. Investors and analysts are closely monitoring how medical device makers will handle any impact from the Trump administration's tariffs and whether they expect benefits from foreign currency fluctuations. Earlier this year, Zimmer said that it would acquire medical device firm Paragon 28 for $1.1 billion, to expand its portfolio of orthopedic surgical devices. Zimmer expects 2025 adjusted profit per share in the range of $7.90 to $8.10, compared with its prior view of $8.15 to $8.35 per share. Analysts were expecting annual profit of $8.19 per share, according to data compiled by LSEG. The Warsaw, Indiana-based company expects currency swings to have a negligible to marginally positive effect on its 2025 revenue, revising its initial forecast of a 1.5% to 2% negative impact to a range of 0% to 0.5%. Last week, peer Stryker Corp reduced its 2025 profit outlook and said it anticipated a $200 million tariff impact in the year. However, Zimmer's first-quarter profit and revenue both came in slightly above expectations, due to strong demand for its devices used in hip and knee procedures. Combined sales at Zimmer's hips and knees units came in at $1.29 billion, compared to $1.28 billion, a year ago. On an adjusted basis, the company posted a profit of $1.81 per share for the quarter ended March 31, topping estimates of $1.77 per share. Zimmer's first-quarter revenue came in at $1.91 billion, slightly ahead of estimates of $1.90 billion. Sign in to access your portfolio